Skip to main content
Contact Us
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
CDMO Intelligence
Real World Data
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Opus Bio
Evaluate
July 28, 2017
Upcoming events – FDA approvals due for Maviret and Besponsa
December 03, 2016
Ash – Relapses spell more CAR-T uncertainty for Juno
April 25, 2016
The next CAR-T target generates promise and caution
March 18, 2016
AACR preview – Novel targets in the spotlight
March 01, 2016
Juno and Kite fight it out to be first to market
January 08, 2016
Juno and Kite follow Novartis to make CAR-T human
December 22, 2015
Therapy focus – How do you solve a problem like CAR-T relapse?
November 06, 2015
ASH preview – Cellectis steals the limelight
October 22, 2015
SITC preview – Macrogenics’ time to shine
April 07, 2015
A settling CAR-T development
January 06, 2015
Amgen takes the CAR for a spin
Load More
Latest Reports
July 27, 2023
H1 Round Up: The haves and the have-nots
July 21, 2023
ADA/EASL eBook
Editor's Picks
July 03, 2023
Astrazeneca and Daiichi’s big reveal disappoints
July 13, 2023
Pharma finds a way to gain weight
July 03, 2023
Protagonist investors flake as psoriasis pill disappoints
June 29, 2023
Approaching datasets for big pharma
June 27, 2023
Nkarta goes back to basics